Acquired pure red cell aplasia due to anti-erythropoietin antibodies in a patient with end stage chronic kidney disease.

Anaemia is a common problem in end stage kidney disease. Recombinant human erythropoietin (rHuEPO) is commonly used in management of such patients to maintain optimal hemoglobin levels and to minimise transfusion requirements. Acquired pure red cell aplasia (PRCA) is a rare complication of erythropoietin therapy due to development of anti-erythropoietin antibodies (anti-EPOabs). We report a patient with end stage kidney disease who developed pure red cell aplasia following rHuEPO treatment.